Loss of exclusivityOctober 2034latest FDA-listed patent expiry
CompanyEMERGENT BIODEFENSE OPERATIONS LANSING INC
Drug detail
Brand name
TEMBEXA
Active ingredient
BRINCIDOFOVIR
Strength
100MG
Dosage form
TABLET
Route
ORAL
Modality
Small molecule
FDA approval
June 2021
Marketing status
RX
Listed patents
Patent
Expires
Type
10112909
October 2034
use U-3165
10487061
October 2034
product
8962829
October 2034
substance, product
9371344
October 2034
product
9303051
July 2034
substance, product
Regulatory exclusivity
Code
Expires
ODE-354
June 2028
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.
TEMBEXA patent cliff — loss of exclusivity October 2034 | CliffBio